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ABSTRACT
Here, we show for the first time, that the familial
breast/ovarian cancer susceptibility gene BRCA1
activates the Notch pathway in breast cells by
transcriptional upregulation of Notch ligands and
receptors in both normal and cancer cells. We dem-
onstrate through chromatin immunoprecipitation
assays that BRCA1 is localized to a conserved
intronic enhancer region within the Notch ligand
Jagged-1 (JAG1) gene, an event requiring "Np63.
We propose that this BRCA1/"Np63-mediated in-
duction of JAG1 may be important the regulation
of breast stem/precursor cells, as knockdown of
all three proteins resulted in increased tumour-
sphere growth and increased activity of stem cell
markers such as Aldehyde Dehydrogenase 1
(ALDH1). Knockdown of Notch1 and JAG1
phenocopied BRCA1 knockdown resulting in the
loss of Estrogen Receptor-a (ER-a) expression and
other luminal markers. A Notch mimetic peptide
could activate an ER-a promoter reporter in a
BRCA1-dependent manner, whereas Notch inhib-
ition using a c-secretase inhibitor reversed this
process. We demonstrate that inhibition of Notch
signalling resulted in decreased sensitivity to the
anti-estrogen drug Tamoxifen but increased expres-
sion of markers associated with basal-like breast
cancer. Together, these findings suggest that
BRCA1 transcriptional upregulation of Notch
signalling is a key event in the normal differentiation
process in breast tissue.
INTRODUCTION
BRCA1 was the ﬁrst identiﬁed breast and ovarian cancer
susceptibility gene responsible for approximately half of
all inherited breast cancer cases (1). Women who carry a
BRCA1 germ line mutation have a cumulative lifetime
risk of 50–85% of developing breast cancer (2). Somatic
BRCA1 mutations are rare in sporadic breast cancer, but
BRCA1 expression is downregulated in 30% of sporadic
cases (3). BRCA1 is known to have multiple roles
including DNA damage repair, cell cycle checkpoint
control, ubiquitination and transcriptional regulation.
Although BRCA1 does not bind to DNA in a sequence
speciﬁc manner, it facilitates transcriptional control at a
number of different levels through its ability to interact
with proteins such as transcription factors, the RNA poly-
merase II holoenzyme complex and proteins involved in
chromatin remodelling [for review see (4)]. Through these
multiple interactions, BRCA1 can co-activate or co-
repress a large number of target genes involved in its
downstream functions.
The mammary gland comprises a branched network of
ductal epithelial structures terminating in alveoli,
composed of two distinct cell types, luminal (secretory)
and basal (myoepithelial). BRCA1 deﬁcient tumours
exhibit characteristics similar to the basal-like subtype of
breast tumours, which resemble the gene expression
pattern of basal epithelial cells (5). These include ‘triple
negative’ receptor status (low ER-a, Progesterone
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Receptor and HER2 expression), strong expression of
basal cytokeratins, high p53 mutation rates, impaired dif-
ferentiation and poor prognosis. BRCA1 expression has
been shown to be required for the differentiation of ER-a-
negative stem/progenitor cells to ER-a-positive luminal
cells with abrogation of BRCA1 leading to increased
stem cell activity (6). Our colleagues have found that
BRCA1 may regulate luminal differentiation through its
ability to transcriptionally activate ER-a (7). BRCA1
mutation carriers have been shown to have an expanded
luminal progenitor population within the breast implying
this subset may be most susceptible to BRCA1 dysfunc-
tion (8,9). When BRCA1 expression is abrogated speciﬁc-
ally in the luminal progenitor subpopulation, mice
develop mammary tumours that phenocopy human
BRCA1 breast cancers (10).
The Notch pathway is a juxtacrine signalling pathway
important for the normal functioning and development of
multiple tissues. The canonical Notch pathway consists of
four receptors (Notch 1–4) and ﬁve ligands [delta-like-1, -3
and -4 (DLL1, DLL3 and DLL4), Jagged1 and Jagged2
(JAG1 and JAG2)]. Notch ligands share a Delta-Serrate-
Lag (DSL) region, which is critical for receptor recogni-
tion and activation. Notch ligand-receptor docking
between two neighbouring cells is followed by two proteo-
lytic cleavages of the respective Notch receptor (including
cleavage by g-secretase) to liberate the cytoplasmic part of
the receptor called the Notch Intracellular Domain
(NICD). The NICD translocates to the nucleus and
recruits histone acetyltransferases to the transcription
factor CBF-1/CSL/RBP-J to form a transcriptional acti-
vation complex on CSL-responsive promoters. Notch
signalling is essential for mammary stem cell commitment
to differentiation, and targeted deletion of Cbf-1 resulted
in increased stem cell activity and aberrant mammary end-
bud formation (11). Mice with Notch1-deﬁcient epithelia
develop spontaneous basal cell-like skin carcinomas (12),
and cre-mediated loss of CSL led to an accumulation of
basal cell clusters during pregnancy and excessive prolif-
eration of basal-like cells in the mammary gland (13).
Notch activation is known to be associated with the tran-
sition from bipotent mammary progenitors to luminally
differentiated populations with Notch3 expression, in par-
ticular, being essential (14). Notch4 activation is
associated with the basal layer and the proliferation of
breast progenitor/stem cells, whereas Notch1, 2 and 3
are all associated with luminal subpopulations
(11,15,16). The Notch pathway may, therefore, be a key
regulator of mammary alveolar development during preg-
nancy by maintaining luminal cell fate and preventing un-
controlled basal cell proliferation.
In this study, we show that BRCA1 activates the Notch
pathway in both non-tumorigenic and breast cancer cells,
in addition to primary breast tumours, through transcrip-
tional upregulation of Notch receptors and ligands. We
ﬁnd that BRCA1 regulates JAG1 gene in a Np63-de-
pendent mechanism. We show that BRCA1, Np63 and
JAG1 may all play roles in stem cell regulation, as
knockdown of all three proteins result in increased
ALDH1 activity and tumoursphere growth. Short
interfering RNA (siRNA) knockdown of Notch signalling
components in this pathway resulted in the loss of markers
associated with basal and luminal differentiation, whereas
proliferation-associated genes and markers of basal-like
breast cancer were increased. We show that knockdown
of Notch1 and JAG1 phenocopy the knockdown of
BRCA1 resulting in the loss of ERa and luminal marker
expression. Exogenous activation of Notch signalling
resulted in increased activation of the ER-a promoter,
whereas Notch inhibition by a g-secretase inhibitor
reversed this process. Consequently, inhibition of the
Notch pathway led to decreased sensitivity to the anti-
estrogen, Tamoxifen, and increased expression of
markers associated with basal-like breast cancer. These
ﬁndings show for the ﬁrst time that BRCA1 may
regulate mammary cell fate through transcriptional acti-
vation of the Notch pathway, ensuring normal basal and
luminal differentiation in breast tissue. Furthermore, the
use of Notch pathway inhibitors for the treatment of ER-a
positive breast cancer may disrupt these signalling mech-




Cell lines were characterized by isoenzyme/cytochrome c
oxidase I assay and short tandem repeat analysis by LGC
Standards. Full details of the HCC-EV/BR, MCF-7,
T47D and HME-1 cell lines are provided in (17). The
184A1 cells are a spontaneously immortalised cell line
derived from reduction mammoplasty tissue and were a
kind gift from Dr Martha Stampfer (University of
California) and maintained as described in (18). shRNA
cells lines were generated as previously described (19).
g-secretase (DAPT Calbiochem) was used at 1 mM.
Treatment of cells with DSL peptide was carried out as
previously described (15). Tamoxifen (Sigma) was used
according to manufacturer’s instructions, and cell viability
was assessed by MTT (Thiazolyl Blue Tetrazolium
Bromide - Sigma). Tumoursphere cultures and Aldeﬂuor
assays were carried out as previously described (19) and
outlined brieﬂy in Supplementary Data.
Murine embryonic stem cells
BRCA1 wild-type and BRCA1 null murine embryonic
stem (ES) cells were a kind gift from Prof. Alan
Ashworth (Institute of Cancer Research, London). ES
cells were grown as previously described (20).
Flow cytometry
Cells were stained with CD49f, EpCAM and CD24 along
with relevant immunoglobulin G (IgG) controls according
to manufacturer’s instructions (BD Biosciences). Data
were analysed as described by Keller et al. (21).
siRNA
siRNA transfection were carried out as previously
described (22). The siRNA sequences are shown in
Supplementary Data.
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Generation of luciferase constructs
The luciferase construct pGL3tkJ1IER was cloned as pre-
viously described (23). Notch 1 promoter region 264 to
228 was PCR ampliﬁed and cloned into pGL3 basic
(pGL3N1). Primers are detailed in Supplementary Data.
Luciferase reporter assays
Luciferase assays were carried out as previously
described (7).
Immunoblot analysis
Immunoblot analysis was performed as previously
described (24). Primary antibodies are listed in
Supplementary Data.
Real-time quantitative PCR
Real-time quantitative PCR (RqPCR) was carried out as
previously described (7). Primers are detailed in
Supplementary Data.
Chromatin immunoprecipitation assays
Chromatin immunoprecipitation (ChIP) assays performed
as previously described (7). Primers used are shown in
Supplementary Data.
Gene expression analysis
Microarray proﬁles of an in-house data set and a
publically available data set (GSE1456) were obtained
(additional information in Supplementary Data).
Samples were background-corrected, normalized and
transformed using the Affy package, justRMA.
Individual probe sets corresponding to genes of interest
were identiﬁed. For each gene, a median value of expres-
sion intensity was calculated from the relevant probe sets.
This median intensity was compared in the two groups,
BRCA1 sporadic versus BRCA1 mutant using boxplots.
Statistical analysis
All relevant data were analysed by two-tailed Students t-
test except Supplementary Figure S7, which was analysed
by Mann–Whitney Two-group Unpaired Test. All data
were deemed signiﬁcant with a P-value of at least <0.05.
All P-values are included in Supplementary Data Set S1.
RESULTS
BRCA1 activates Notch signalling
Following microarray analysis, we identiﬁed several Notch
pathway genes as BRCA1 upregulated targets following
reconstitution of wild-type BRCA1 into BRCA1 mutant
HCC1937 cells (25). We validated by western blotting
[Figure 1A (i)] and by RqPCR [Figure 1A (ii)] that Notch
ligands JAG1 and DLL-1 and receptors Notch1, 2, and 3
were all BRCA1 transcriptional targets. Conversely,
siRNA knockdown of BRCA1 in BRCA1 wild-type
MCF-7 (Figure 1B and Supplementary Figure S1A) and
T47D (Figure 1C and Supplementary Figure 1B) cells
resulted in reduced protein and mRNA levels of the same
Notch pathway genes. These data suggest that BRCA1
may impact on Notch signalling through simultaneous
transcriptional upregulation of both receptors and
ligands, although transcriptional upregulation does not ne-
cessarily mean activation. Therefore, to demonstrate that
BRCA1 could activate the Notch pathway, we used a
b-globin promoter reporter construct (pSH2), which
contains a CSL/Notch responsive element shown to be a
reliable readout ofNICD-mediated gene transcription (26).
A JAG1mimicking peptide (DSL) was used to exogenously
activate Notch receptors. We only observed optimal DSL-
mediated Notch activation in cells expressing wild-type
BRCA1 [Figure 2A (i) and (ii)]. Conversely, knockdown
of BRCA1 in MCF-7 and T47D cells resulted in reduced
DSL-mediated activity (Figure 2B and C). Together, these
data support the theory that BRCA1, through its ability to
transcriptionally upregulate Notch ligands and receptors,
facilitates Notch signalling and ensures that a Notch tran-
scriptional program is functional in normal breast tissue.
BRCA1 activates JAG1 but not Notch1 through a
"Np63-dependent mechanism
Next, we wanted to deﬁne the mechanism basis of Notch
activation by BRCA1. BRCA1 cannot bind DNA itself
and must be recruited to promoters through its ability to
bind to other transcription factors. We have recently
identiﬁed Np63g as a BRCA1 interacting protein, an
interaction that appears to be important for the transcrip-
tional regulation of a number of key BRCA1 target genes
including p63 itself, which BRCA1 upregulates through a
positive autoregulatory loop (19). Notch1 is known to be a
p53 target gene (27), whereas JAG1 is speciﬁcally a tran-
scriptional target of p63 (not p53) and contains a number
of p63 responsive elements located in intron 2 (23). Notch1
and JAG1 were therefore selected for further investigation
to deﬁne the mechanism underpinning their regulation by
BRCA1. We generated luciferase reporter constructs con-
taining the p53 responsive element of the Notch1 promoter
(pGL3N1) and the p63 response elements in intron 2 region
of the JAG1 gene cloned upstream of a minimal thymidine
kinase promoter (pGL3tkJ1) [location of both regions
shown in Figure 3A (i)]. In agreement with ﬁndings from
Figures 1 and 2, we found that both constructs were
regulated in a BRCA1-dependent manner [Figure 3A (ii)
and B (i), respectively]. As HCC1937 cells possess a mutant
truncated p53, we hypothesised that the BRCA1 regulation
of both genes may be dependent on p63, not p53, as these
often bind to the same response elements in promoters.
SiRNA knockdown of BRCA1 in MCF-7 cells resulted
in a signiﬁcant reduction in p63 mRNA species, consistent
with our previous ﬁndings [Figure 3B (ii)]. Using ChIP
assay, we could demonstrate the localization of both
BRCA1 and p63 to the JAG1 internal enhancer region,
IER [Figure 3C (i)]. Indeed, siRNA depletion of p63
resulted in a signiﬁcant reduction in JAG1-IER reporter
activity, comparable with BRCA1 siRNA [Figure 3C (ii)]
with equivalent reduction of JAG1 mRNA following
Np63 and BRCA1 siRNA but less signiﬁcantly with
TAp63 siRNA (Supplementary Figure S2A). We could
demonstrate by ChIP assay that BRCA1 required p63 for
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recruitment to the JAG1-IER, as siRNA knockdown of
Np63 [Figure 3D (i)] resulted in loss of BRCA1 recruit-
ment to this region [Figure 3D (ii)]. Finally, we showed that
both BRCA1 and Np63 are required for optimal expres-
sion of JAG1 [Supplementary Figure S2B].
Preliminary work investigating BRCA1 regulation of
the Notch1 promoter has suggested an alternative mech-
anism may be involved, as p63 knockdown does not
appear to alter Notch receptor levels and although
BRCA1 is localized on the Notch promoter, p63 is not
[Supplementary Figure S3A (i) and (ii)]. This reﬂects the
fact that both p63 and JAG1 are basally restricted genes,
whereas Notch receptors 1–3 are associated with the
luminal layer in breast ducts [also supported by RqPCR
analyses of Notch1-3 in a breast cancer cell line panel,
Supplementary Figure S3B (i–iii)]. BRCA1 regulation of
Notch1 is independent of p53 [Supplementary Figure S3C
(i) and (ii)], and our preliminary RqPCR, luciferase and
Figure 1. (A) (i) Immunoblots of HCC1937 cells stably transfected with an empty vector (EV) or an expression construct containing wild-type
BRCA1 (BR). Blots were probed with the antibodies shown and reprobed with b-tubulin as a loading control. (ii) RqPCR of the same cell lines
described in (i) with primers speciﬁc for Notch receptors and ligands. (B) (i) Immunoblot of MCF-7 cells following scrambled (Scr) control or
BRCA1 (BRsi)-speciﬁc siRNA treatments. Blots were probed with the antibodies shown and reprobed with b-tubulin as a loading control.
(ii) RqPCR of the cells described in (i) with primers speciﬁc for Notch receptors and ligands. (C) (i) Immunoblot of T47D cells following the
siRNA treatments described for MCF-7 cells with (ii) the same corresponding RqPCR analyses.
8604 Nucleic Acids Research, 2013, Vol. 41, No. 18
ChIP data suggest that this may be dependent on the
luminal gene, GATA3 (28) [Supplementary Figure S4A
(i–iii)]. This consistent with our recent ﬁndings where we
have shown that BRCA1 interacts with GATA3 and
represses the expression of basal genes in a GATA3-de-
pendent fashion (29). Taken together, these experiments
deﬁne the mechanistic basis of JAG1 regulation showing
that BRCA1 activates JAG1 transcription through a
p63-dependent process, whereas BRCA1 regulates the
Notch receptors through a p63- (and p53)-independent
mechanism, possibly involving GATA3.
BRCA1 may regulate breast stem/progenitor function
through Notch signalling
BRCA1 has been postulated to be a regulator of breast
stem cell function (6), and p63 has been implicated in the
Figure 2. (A) (i) Immunoblot of HCC EV and BR cells probed for BRCA1 and reprobed with b-tubulin as a loading control. (ii) Luciferase reporter
assay of HCC EV and BR cells following transfection of a Notch-responsive b-globin reporter construct (pSH2) and an empty vector control (pyLuc)
with co-transfection of a Renilla luciferase construct used for transfection control. Cells were pretreated with a scrambled peptide (con) or a Notch
ligand mimicking peptide (DSL). (B) (i) Immunoblot of MCF-7 cells following scrambled (Scr) control or BRCA1 (BRsi)-speciﬁc siRNA treatments.
Blot was probed for BRCA1 and reprobed with b-tubulin as a loading control. (ii) Reporter assay was performed as described in (A) (ii).
(C) (i) Immunoblot of T47D cells following the siRNA treatments described for MCF-7 cells with (ii) the reporter assay as described in (A) (ii).
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Figure 3. (A) (i) Diagram showing the p53- and p63-binding sites of the Notch1 and JAG1 genes relative to the respective transcriptional start sites
(TSS). (ii) Luciferase reporter assay of HCC EV and BR cells following transfection of either a Notch1 promoter (pGL3N1) or JAG1 enhancer
(pGL3tk J1IER) reporter constructs, co-transfected with a Renilla luciferase control construct. (B) (i) Luciferase assay of MCF-7 cells using the same
reporter constructs following scrambled (Scr) control or BRCA1 (BRsi)-speciﬁc siRNA treatments. (ii) RqPCR of MCF-7 cells showing mRNA
levels of pan-, TA- and N- p63 transcripts following scrambled (Scr) control or BRCA1 (BRsi) speciﬁc siRNA. (C) (i) ChIP assay showing
localization of RNA polymerase II (RNA Pol II), p63 and BRCA1 on the JAG1 enhancer (Jagged1-IER). One percent of sonicated lysate before
immunoprecipitation was used as positive control (input) and IgG pulldown used as negative control (IgG control). (ii) Luciferase assay of MCF-7
cells using the JAG1 enhancer reporter (J1IER) co-transfected with a Renilla luciferase control construct following scrambled (Scr) control, BRCA1
(BRsi) or p63 (p63si) siRNA. (D) (i) RqPCR of MCF-7 cells showing knockdown of Np63 and Jagged-1 following treatment with scrambled (Scr)
control or Np63 (Np63si) siRNA. (ii) ChIP assay showing recruitment of BRCA1 and p63 on the JAG1 enhancer (Jagged1-IER) following
scrambled (Scr) control or total p63 (p63si) siRNA. Positive and negative controls are as outlined for (C) (i). In addition, PCR using primers speciﬁc
for a region upstream (+2kb J1ER) of the JAG1 enhancer shows the speciﬁcity for the Jagged1-IER.
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stem cell regulation of a number of different tissue types
(30). We have previously shown that loss of BRCA1 and
p63 in MCF-10A cells leads to an increase in stem/pro-
genitor cells (19). We therefore wanted to investigate
whether the Notch pathway acts an effector pathway
downstream of BRCA1 and p63 in stem cell regulation.
Knockdown of BRCA1, Np63 or JAG1 in MCF-7 cells
decreased Notch activity, and all resulted in enhanced
tumoursphere growth (Figure 4A (i) and Supplementary
Figure S5A). Indeed, monolayer cultures of MCF-7 cells
with stable shRNA knockdown of these three genes all
showed enhanced Aldeﬂuor activity [Figure 4A (ii)].
Although neither tumoursphere culturing nor Aldeﬂuor
activity are wholly deﬁnitive of stem cell function, this
suggests that normal differentiation process has been
altered. Using RqPCR, we observed that knockdown of
p63 or JAG1 correlated with loss of a number of markers
associated with luminal differentiation such as muc1 and
CD61 as well as basal markers such as CD10 and CD44
[Figure 4B (i) and (ii), Supplementary Figure S5B (i) and
(ii)]. Knockdown of JAG1 or Np63 resulted in the
upregulation of proliferation-associated markers (FoxM1
and CXCL1) and markers commonly associated with
basal-like breast cancer (p-cadherin, CXCL1 and
CTPS1) [Figure 4B (iii) and (iv), Supplementary
Figure S5B (iii) and (iv)]. This did not appear to be
associated with a generalized non-speciﬁc expansion of
increased stem cell markers, as expression of genes such
as Nanog were actually reduced, whereas other stem cell
markers like CXCR4 were increased (Figure 4B and
Supplementary Figure S5B). Using the cell surface
markers CD49f, EpCAM and CD24 (21), we observed
a decrease in progenitor and mature populations with
an increase in the putative stem cell population
(Supplementary Figure S6A). We did note, however, the
intensity of the CD49f staining was decreased compared
with scrambled control, indicating that this may represent
an aberrant expanded population distinct from the clas-
sical CD49f high stem cell population. Inhibition of the
Notch pathway in MCF-7 and T47D cells through either
Notch receptor siRNA or the use of chemical inhibitors
(GSI) showed similar effects on tumoursphere formation,
Aldeﬂuor activity and changes in marker expression
observed following JAG1 and Np63 siRNA, suggesting
that Notch signalling is important for luminal-basal cell
fate determination in breast tissue (Figure 5 and
Supplementary Figure S6).
To investigate whether this mechanism was a general
phenomenon and also present in non-cancerous normal
cells, we used murine ES cells lacking wild-type Brca1
(20) grown in the presence and absence of leukemia
inhibitory factor (LIF) (to prevent and promote differen-
tiation, respectively). We observed that Brca1 regulated
the expression of both basal and luminal components of
the Notch signalling pathway in normal cells [Figure 5C
(i)]. In contrast to the more differentiated breast cancer
cell lines, Notch4 was readily detectable in the ES cells,
whereas Notch3 expression levels were difﬁcult to detect,
reﬂecting the known expression patterns and functional
roles of these two genes in differentiation and develop-
ment (14). To look more speciﬁcally at BRCA1-dependent
regulation of the Notch receptors and ligands in the
normal breast, we used two pseudo-normal breast cancer
cell lines—HME-1 h-TERT immortalized cells and spon-
taneously immortalized 184A1 cells. siRNA-mediated
knockdown of BRCA1 resulted in downregulated expres-
sion of Notch receptors and ligands [Figure 5C (ii)] con-
sistent with our results from breast cancer cell lines and
the ES cells. Next, we wanted to extend our studies into
patient samples, as siRNA knockdown of genes in cell
lines may not adequately represent the complex and het-
erogeneous nature of BRCA1 mutations in vivo including
interactions of BRCA1 mutant breast cells with stromal
and immune compartments. We therefore used gene ex-
pression data from a small in-house data set of 10 BRCA1
mutant and 10 sporadic breast cancer patients as well as a
publically available data set containing BRCA1 mutant
and sporadic breast cancer cases (31). Consistent with
our results from cell line models, we observed decreased
expression of Notch pathway signalling components and
differentiation markers in BRCA1 mutant proﬁles,
whereas the expression of stem cell-like, proliferation
and basal-like markers were increased (Supplementary
Figure S7). Together, we conclude that Notch signalling
downstream of BRCA1 is important in the ordered differ-
entiation and growth control of basal and luminal precur-
sors in both normal and cancerous breast tissue.
Our colleagues have previously shown that BRCA1
transcriptionally regulates a number of basal and
luminal terminal differentiation markers at the promoter
level, determining commitment to a particular cell fate
within the mammary gland (32). For example, exogenous
expression of functional BRCA1 in BRCA1 mutant cells
results in the reduced expression of basal genes, such as p-
cadherin and the upregulation of luminal genes such as
cytokeratin 18 and ER-a [Figure 6A (i)]. Notch signalling
has also been implicated in mammary epithelial cell dif-
ferentiation in the murine mammary gland, and the Notch
target gene GATA3 is strongly associated with the expres-
sion of the luminal marker ER-a in mammary epithelial
cells and for maintaining luminal characteristics in breast
cells (33). We wanted to assess the functional conse-
quences of Notch1 and JAG1 downstream of BRCA1 in
mammary epithelial cell fate. Using knockdown of both
genes in MCF-7 cells, we found that both were required
for the expression of luminal genes GATA3 and ER-a.
[Figure 6A (ii) and (iii)]. Notch1 expression was not
required for suppression of the basal genes smooth
muscle actin and p-cadherin, whereas JAG1 knockdown
was accompanied by upregulation of both these basal
marker genes (in agreement with the restricted expression
of JAG1 to basal epithelia), though this was not statistic-
ally signiﬁcant. To test the link between Notch activation
and the expression of luminal marker genes, we used a
reporter construct containing the proximal AB promoter
regions (proAB) of the ER-a gene (7). BRCA1 mutant
cells were unable to drive transcription from this
promoter even in the presence of DSL treatment,
whereas cells expressing wild-type BRCA1 showed a sig-
niﬁcant increase in activation over treatment with a
control peptide [Figure 6B (i)]. Similar results were also
seen using siRNA knockdown of BRCA1 in MCF-7 and
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T47D cells [Figure 6B (ii) and (iii)]. Alternatively, as
Figure 6C (i) shows, activation of the ER-a promoter con-
struct in MCF-7 cells with DSL stimulation was almost
completely abolished by treatment with the g-secretase in-
hibitor. Similar results were also seen at a protein level in
MCF-7 and T47D cells (Figure 6C (ii) and (iii), respect-
ively). Having shown the importance of Notch signalling
in luminal differentiation and ER-a expression, we wanted
to investigate whether the therapeutic use of Notch
pathway inhibitors, such as g-secretase inhibitors, would
alter the response to anti-estrogen therapy. Inhibition of
the Notch pathway by siRNA-mediated knockdown of
JAG1 (Supplementary Figure S8A) in MCF-7 cells
resulted in an impaired growth inhibitory response to
the antiestrogen, Tamoxifen [Figure 6D (i)], suggesting a
loss of ER-a dependent signalling. The use of a g-secretase
inhibitor in combination with tamoxifen did not appear to
produce even additive effects and actually appeared to
slightly (but signiﬁcantly) protect MCF-7 cells at higher
tamoxifen concentrations [Figure 6D (ii)]. Similar results
were also observed using T47D cells (Supplementary
Figure S8B–D). In addition, the use of a g-secretase inhibi-
tor led to the loss of ER-a and GATA-3 expression as well
as an observed increase in the expression of proliferation
markers (CXCL1) and basal-like breast cancer markers
(p-cadherin, CTPS1 and FOXC1) [Figure 6D (iii)].
Figure 4. (A) (i) Tumoursphere cultures of MCF-7 cells following infection with retroviruses containing shRNA constructs for control (pSuper),
BRCA1 (BRsh#9), Np63 (Np63sh) and JAG1 (JAG1sh) knockdowns. Tumourspheres were counted and expressed as %Mammary Forming
Units (MFUs) relative to pSuper. (ii) The same MCF-7 shRNA cell lines were assayed for Aldeﬂuor activity using ALDEFLUOR and expressed as
percentage Aldeﬂuor-positive (%ALDH+). (B) RqPCR of luminal and basal markers in MCF-7 cells treated with (i) scrambled (Scr) control or
JAG1 siRNA, (ii) scrambled (Scr) control or Np63 siRNA. RqPCR of stem cell and basal-like markers in MCF-7 cells treated with (iii) scrambled
(Scr) control or JAG1 siRNA or (iv) scrambled (Scr) control or Np63 siRNA. b-tubulin mRNA was used for normalization.
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Figure 5. (A) Tumoursphere cultures of (i) MCF-7 or (iii) T47D cells treated with Scrambled (Scr), Notch1 (Notch1#2), Notch2 (Notch2#2), Notch3
(Notch3#2), a combination of Notch1, 2 and 3 (Notch1,2&3#2) or Gamma Secretase Inhibitor (GSI). Tumourspheres were counted and expressed as
% Mammary Forming Units (MFUs) relative to control. Aldeﬂuor activity assay of the same (ii) MCF7 and (iv) T47D cells with % Aldeﬂuor
positive cells calculated and shown. (B) RqPCR of lineage and stem cell markers in MCF-7 cells treated with Scrambled (Scr) or (i) Notch1 (Notch1
si), (ii) Notch2 (Notch2 si) or (iii) Notch3 (Notch3 si) siRNA. (C) (i) RqPCR for components of the Notch pathway in Brca1 wild-type (Brca1+/+)
and Brca1 null (Brca1 /) murine ES cells grown in the presence (+LIF) or absence (LIF) of LIF for 4 days. (ii) RqPCR for components of the
Notch pathway in HME1 and 184A1 normal breast cell lines transiently transfected with either scrambled (Scr) or BRCA1 (BRsi)-speciﬁc siRNA.
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Figure 6. (A) (i) Immunoblots of HCC EV and BR cells probed with the antibodies shown and reprobed with b-tubulin as a loading control.
(ii) RqPCR of MCF-7 cells showing mRNA levels of basal and luminal markers following scrambled (Scr) control or Notch1 (N1si)-speciﬁc siRNA.
(iii) RqPCR of MCF-7 cells showing mRNA levels of the same basal and luminal markers following scrambled (Scr) control or JAG1 (J1si)-speciﬁc
siRNA. (B) (i) Luciferase reporter assay of HCC EV and BR cells following transfection of either an empty vector (pGL3) or a reporter vector
containing the AB regions of the ERa promoter (pGL3-ERproAB), co-transfected with a Renilla luciferase control construct. Cells were treated with
either a scrambled peptide (control) or a Notch ligand mimicking peptide (DSL) before assay. (ii) Luciferase reporter assay of T47D cells using the
8610 Nucleic Acids Research, 2013, Vol. 41, No. 18
(continued)
Together, these data highlight (i) the importance of Notch
signalling downstream of BRCA1 and suggest an inter-
dependence between Notch and estrogen signalling to
maintain the luminal phenotype and (ii) how inhibition
of Notch signalling may lead the disruption of normal
mammary differentiation leading to the emergence of
more aggressive basal-like cancer subtypes.
DISCUSSION
In this study, we show that BRCA1 activates the Notch
pathway in breast cells by transcriptionally upregulating
Notch ligands and receptors in both normal and cancer
cells. We show the mechanism through which BRCA1
regulates the Notch ligand JAG1, an event that is depend-
ent on Np63 expression. Knockdown of either Notch1
or JAG1 phenocopies BRCA1 knockdown resulting in
the loss of ERa and luminal marker expression. We
show that we can drive ERa expression through Notch
activation, whereas a g-secretase inhibitor reversed this
process and abrogated the ability of cells to respond to
ERa targeted therapy. Knockdown of BRCA1, Np63 or
JAG1 in MCF-7 cells resulted in increased tumoursphere
growth and ALDH1 activity. Knockdown of Notch
signalling components in luminal cells also resulted in
decreased expression of some stem and progenitor
markers but upregulation of proliferation-associated
markers and markers of basal-like breast cancer. This is
accompanied by an increase in a stem cell-like population
as shown by ﬂow cytometry. Together, these ﬁndings
suggest that BRCA1 regulation of Notch signalling is im-
portant in the normal differentiation process in breast
tissue, and that loss of this pathway may be a key event
in the progression of basal-like breast cancers.
Here, we show that Notch signalling downstream of
BRCA1 may be central to normal breast differentiation,
as we see regulation of the Notch pathway by BRCA1 in
non-tumorigenic mammary cell lines derived from reduc-
tion mammoplasty as well as in murine ES cells. This is in
keeping with the observation that the Notch signalling
pathway was differentially expressed in cells from
BRCA1 mutation carriers when compared with wild-
type (9). It is also evident from a number of other
studies that Notch signalling must also be tightly
controlled. Overexpression of NICD1 or RBP-Jk results
in the transformation of normal breast epithelial cells (34),
whereas Notch3 has been shown to play an important
tumour suppressive role through its ability to upregulate
p21cip1/WAF1 and induce senescence (35). Activation of
Notch signalling in ERa-negative breast cells has been
linked with the suppression of apoptosis through upregu-
lation of survivin (36), inferring that the increased sensi-
tivity of ERa-negative breast cells to Notch inhibition was
possibly due to their ‘addiction’ to the Notch pathway
(36). Simultaneous inhibition of EGFR and Notch
activity has been shown to result in a synthetic lethality
in basal-like breast cancer (37). Rizzo and colleagues also
showed that ERa signalling actually inhibited Notch
receptor activity and Notch NICD nuclear levels, an
effect reversed following treatment with tamoxifen (38).
In our study, however, we observe low/absent Notch
signalling in ERa-negative breast cells as well as in
BRCA1 mutant cell lines. Our study contradicts the
ﬁndings of the studies described earlier in the text for a
number of reasons including (i) the fact that these studies
used overexpressed NICD1 (which does not reﬂect the
normal physiological scenario); (ii) instead of targeting
speciﬁc Notch receptors, such studies performed pan-
Notch inhibition with g-secretase inhibitors (which will
also inhibit TGFa cleavage and hence EGFR activation)
(36); and (iii) the studies of Haughian et al. (39) and Rizzo
et al. (40) use models of anti-estrogen therapy resistance,
whereas we use therapy naı¨ve cells. In addition, ERa-
negative breast cancers are known to show a high degree
of heterogeneity and have been subclassiﬁed into at least
two different subgroups (41). It is likely that not all ERa-
negative breast cancers share dysfunctions in BRCA1
signalling and that intrinsic subgroups may show normal
or indeed constitutively active Notch signalling.
Furthermore, the Notch pathway has been shown to act
downstream of p53 in the repression of mammary stem/
progenitor cells (42). Therefore, the p53 mutational status
of the cell lines models used in studies may also partly
explain discrepancies between our results and others.
JAG1 expression has been shown to be restricted to
basal cells and its overexpression has been linked to
basal-like breast cancer (43). BRCA1 mutant breast
tumours have been reported to express higher levels of
JAG1 mRNA compared with BRCA2 mutant tumours;
however, this was not signiﬁcant (44). Contrary to these
observations, we consistently observed a positive associ-
ation between BRCA1 function and JAG1 expression in
both cell lines and patient samples. Although our BRCA1
knockdown and reconstitution studies in cell lines are con-
sistent, reliance on in vitro models may not accurately
reﬂect the in vivo scenario where cell–stromal interactions
and immunoediting will signiﬁcantly impact on tumour
behaviour. Using patient data, we observed that the cor-
relation between BRCA1 mutational status and expres-
sion of Notch receptors and ligands (in addition to some
Figure 6. Continued
same reporter contructs pre-treated with either scrambled control (Scr) or BRCA1 (BRsi)-speciﬁc siRNA Cells were treated with either a scrambled
peptide (Con) or a Notch ligand-mimicking peptide (DSL) before assay. (iii) Western blot of MCF7 cells treated with scrambled (Scr) or BRCA1
(BRsi)-speciﬁc siRNA followed by either a scrambled peptide (Con) or Notch ligand-mimicking peptide (DSL). Blots were then probed for ER-a and
GAPDH as a loading control. (C) (i) Luciferase reporter assay of MCF-7 cells using the same reporter constructs as (B), but instead cells were
treated with either DSL alone or DSL combined with a Gamma Secretase Inhibitor (GSI&DSL). Immunoblot of (ii) MCF-7 or (iii) T47D cells
treated with Gamma Secretase Inhibitor (GSI) or vehicle control (Con) for 24 h. Blots were probed with ER-a or GAPDH as a loading control.
(D) (i) Dose response curve of MCF-7 cells treated with different doses of Tamoxifen (Log10 M) (for 72 h) following treatment with scrambled (SCR)
control or JAG1 (JAG1si)-speciﬁc siRNA. (ii) Dose response curve of MCF-7 cells treated with different doses of Tamoxifen (Log10 M) following
pre-treatment with Gamma Secretase Inhibitor (GSI). (iii) RqPCR of MCF-7 cells treated with either Gamma Secretase Inhibitor (GSI) or vehicle
control (Con) for 24 h.
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of the downstream differentiation and proliferation genes
highlighted) is stronger in our in-house data set compared
with the Pawitan data set (31). This may reﬂect the fact
that in our in-house data set, we were able to stratify
BRCA1 mutant proﬁles based on triple negativity, and
these tumours were therefore more likely to consistently
display the ‘BRCAness’ phenotype (45). It must be con-
sidered that although triple negativity is enriched in
BRCA1 mutant proﬁles, not all BRCA1 tumours may
possess a triple negative phenotype. In the Pawitan data
set, this information was not available, and therefore our
comparison may have included a small number of BRCA1
mutant tumours expressing one or several of ERa, PR or
HER2, in addition to sporadic cases possessing
‘BRCAness’ characteristics, both of which will complicate
any comparison.
Our data indicate that loss of the BRCA1/p63/Notch
signalling axis results in an increase in an aberrant popu-
lation with cancer stem cell properties. However, the
decrease in some of the cancer stem cell markers such as
Nanog implies that this may represent an as yet unclassi-
ﬁed cancer stem cell population. Numerous studies have
demonstrated that the cancer stem cell phenotype is het-
erogeneous (46) with one study showing at least two
distinct populations with cancer stem cell characteristics
and Notch1 expression in cell lines derived from a Brca1
knockout mouse model (47). In addition, a recent publi-
cation has demonstrated a Notch-independent population
of breast cancer stem cells within the MCF-7 cell line (48)
further highlighting the heterogeneity of stem cells.
Some of our ﬁndings are not in keeping with the results
of Harrison et al. (16) who showed that genetic or
pharmacologic inhibition of Notch1 (and Notch4)
reduced stem cell activity. This may result from the use
of different cell surface antigens to identify the stem cell-
like population (EpCAM/CD44/CD24 versus EpCAM/
CD49f/CD24). In agreement with our ﬁndings, Keller
et al. (21) have shown that use of CD44 does not accur-
ately stratify cell lines based on tumour subtype, whereas
CD49f mimics the ﬁndings seen by gene expression
analysis and also in primary breast samples. We observe
a reduction in CD44 expression following loss of Notch
signalling, suggesting that our aberrant population would
not be detected by the methods used in the Harrison study.
In summary, we believe the apparent BRCA1-Notch dis-
crepancy with our study reﬂects the (i) heterogeneous
nature of the cancer stem cell phenotype; (ii) experimental
differences such as use of different techniques and cell
surface antigens to identify stem-like cells; and (iii) differ-
ences in the p53 status, which can have inﬂuence on stem
cell function (as discussed earlier in the text).
We also observe similar BRCA1-dependent effects fol-
lowing Np63 knockdown. We believe this is signiﬁcant
ﬁnding, as our group has also recently identiﬁed the
Np63 family of proteins as downstream transcriptional
targets of BRCA1 (19). We have demonstrated that
BRCA1 interacts with Np63g and requires Np63 ex-
pression to transactivate JAG1. It is known that Notch
signalling and Np63 expression are mutually antagonis-
tic, and the two pathways act to control the luminal and
basal compartments, respectively, in breast tissue (49).
We believe that the BRCA1-Np63g complex is import-
ant for transcriptionally upregulating genes involved in
normal basal differentiation and for transmitting a
Notch-responsive signal to adjacent cells through tran-
scriptional upregulation of JAG1 (and probably other
Notch ligands). Adjacent cells would thus adopt a
Notch-responsive transcriptional program leading to the
enforcement of luminal differentiation through ERa and
GATA3 signalling (50). This event would appear to be
important for maintaining growth control of uncommitted
or bipotent progenitor cells, as loss of BRCA1, Np63
or JAG1 all show similar phenotypes including loss of
differentiation markers, enhanced proliferation of
tumourspheres and upregulation of proliferation-
associated markers. In summary, we have identiﬁed a
number of Notch proteins as key transcriptional targets
of the breast/ovarian cancer tumour suppressor gene
BRCA1. We show that control of Notch signalling is an
important aspect of BRCA1 tumour suppression with
roles in the differentiation, basal-luminal lineage speciﬁca-
tion and growth control of breast tissue. These ﬁndings
are likely to have implications for the management of
breast cancer patients and a greater understanding of the
intricacies of Notch signalling and breast development
may be of great beneﬁt in the future design of breast
cancer chemotherapies.
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